ESLA: Estrella Immunopharma, Inc. Stock

by  •  • Comments Off on ESLA: Estrella Immunopharma, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 36.19
Enterprise Value ($M) 34.39
Book Value ($M) 0.75
Book Value / Share 0.02
Price / Book 48.49
NCAV ($M) -0.75
NCAV / Share -0.02
Price / NCAV -48.02

Profitability (mra)
Return on Invested Capital (ROIC) -11.75
Return on Assets (ROA) -0.32
Return on Equity (ROE) -0.88

Liquidity (mrq)
Quick Ratio 0.75
Current Ratio 0.75

Balance Sheet (mrq) ($M)
Current Assets 2.24
Assets 3.74
Liabilities 2.99
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -7.31
Net Income -7.31

Cash Flow Statement (mra) ($M)
Cash From Operations -16.07
Cash from Investing 4.96
Cash from Financing 12.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2023-10-30 13D Eureka Therapeutics, Inc. 71.80 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PUR
2024-10-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2024 ☐ TRANSITI
2024-09-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUAN
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURS

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-26 8,386 24,433 34.32
2024-11-25 8,799 51,996 16.92
2024-11-22 925 13,696 6.75
2024-11-21 3,614 18,032 20.04

(click for more detail)

Similar Companies
EPIX – ESSA Pharma Inc. EQ – Equillium, Inc.
ERNA – Eterna Therapeutics Inc. EVOK – Evoke Pharma, Inc.
EYEN – Eyenovia, Inc.


Financial data and stock pages provided by
Fintel.io